Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: Report from the children's oncology group

Pediatric Blood and Cancer

Volumn 61, Issue 1, 2014, Pages 102-106

  Nageswara Rao, Amulya A ^a   Wallace, Dana J ^b   Billups, Catherine ^b   Boyett, James M ^b   Gajjar, Amar ^b   Packer, Roger J ^c,d  

^a MAYO CLINIC   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Average risk medulloblastoma; Cumulative cisplatin dose; Survival outcomes

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; LOMUSTINE; VINCRISTINE; CORTICOSTEROID; CREATININE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CRANIOSPINAL IRRADIATION; CREATININE CLEARANCE; DRUG DOSE REDUCTION; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FEMALE; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OPTIMAL DRUG DOSE; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TUMOR RECURRENCE; CANCER RADIOTHERAPY; FOLLOW UP; GLOMERULUS FILTRATION RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; ADJUVANT CHEMOTHERAPY; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; KAPLAN MEIER METHOD; MAINTENANCE CHEMOTHERAPY; MORTALITY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MALE; MEDULLOBLASTOMA; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; YOUNG ADULT;

EID: 84891694479     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24670     Document Type: Article

References (25)

1. CBTRUS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2007.
2. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: New biological advances. Lancet Neurol 2007;6:1073-1085.
3. Packer RJ,Vezina G. Management of and prognosis with medulloblastoma: Therapy at a crossroads. Arch Neurol 2008;65:1419-1424.
4. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24: 4202-4208.
5. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-820.
6. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: Recent advances and future challenges. Semin Oncol 2004;31:666-675.
7. Turner CD, Rey-Casserly C, Liptak CC, et al. Late effects of therapy for pediatric brain tumor survivors. J Child Neurol 2009;24:1455-1463.
8. Brock P, Pritchard J, Bellman S, et al. Ototoxicity of high-dose cis-platinum in children. Med Pediatr Oncol 1988;16:368-369.
9. Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006;107:417-422.
10. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991;19:295-300.
11. Cohen BH, Zweidler P, Goldwein JW, et al. Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg 1990;16:292-296.
12. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: Prevalence, educational performance, and functional status. Ear Hear 1998;19:339-354.
13. Gurney JG, Tersak JM, Ness KK, et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the children's oncology group. Pediatrics 2007;120:e1229- e1236.
14. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: Results from the childhood cancer survivor study. Radiat Res 2010;174:840- 850.
15. Lefkowitz IB, Packer RJ, Siegel KR, et al. Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. Cancer 1990;65:412-417.
16. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690-698.
17. Laurell G, Bagger-Sjoback D. Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 1991;20:158-167.
18. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005;23:8588-8596.
19. Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012;30:2408-2417.
20. Walker DA, Pillow J,Waters KD, et al. Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol 1989;17:48-52.
21. Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008;26:3749-3755.
22. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;25:708-714.
23. Riedemann L, Lanvers C, Deuster D, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 2008;8:23-28.
24. Ross CJ, Katzov-Eckert H, Dube MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009;41:1345-1349.
25. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: The current consensus. Acta neuropathol 2012;123:465-472.